SCHEMBL13892191

SCHEMBL13892191

COCCOCCC(=O)Nc1ccc(CCC(=O)NCCC(N)=O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.48
KDM4E B2RXH2 1/20 0.48
CA12 O43570 2/20 0.47
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA4 P22748 2/20 0.47
CA9 Q16790 2/20 0.47
CA14 Q9ULX7 2/20 0.47
KMT2A Q03164 5/20 0.47
MEN1 O00255 3/20 0.47
ALDH1A1 P00352 2/20 0.47
NAMPT P43490 1/20 0.45
POLB P06746 1/20 0.44
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13892138 0.93 LMNA (0.52) LMNAKDM4EKMT2AMEN1ALDH1A1
SCHEMBL14147681 0.90 CA12 (0.48) LMNAKDM4ECA12CA1CA2
SCHEMBL13892132 0.90 HDAC1 (0.51) CA12CA1CA2CA4CA9
SCHEMBL13881005 0.89 LMNA (0.48) LMNAKDM4ECA12CA1CA2
SCHEMBL13892140 0.88 PKM (0.50) LMNAKDM4ECA12CA1CA2
SCHEMBL18643483 0.88 CA12 (0.52) LMNAKDM4ECA12CA1CA2
SCHEMBL18643445 0.82 CA12 (0.47) LMNAKDM4ECA12CA1CA2
SCHEMBL13892139 0.82 HDAC3 (0.66) CA12CA1CA2CA9KMT2A
SCHEMBL13880992 0.81 LMNA (0.52) LMNAKDM4EKMT2AMEN1ALDH1A1
SCHEMBL13880993 0.78 HDAC1 (0.51) CA12CA1CA2CA4CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090098130-A1 GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS COVX TECHNOLOGIES IRELAND LIMITED (IE) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090098130-A1 GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS GLP1R, GIPR, GCGR LMNA 3628/4885KDM4E 3704/4885CA12 2579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.